These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 2553920

  • 1. Kappa opiate receptor multiplicity: evidence for two U50,488-sensitive kappa 1 subtypes and a novel kappa 3 subtype.
    Clark JA, Liu L, Price M, Hersh B, Edelson M, Pasternak GW.
    J Pharmacol Exp Ther; 1989 Nov; 251(2):461-8. PubMed ID: 2553920
    [Abstract] [Full Text] [Related]

  • 2. Further demonstration of kappa opioid binding sites in the brain: evidence for heterogeneity.
    Su TP.
    J Pharmacol Exp Ther; 1985 Jan; 232(1):144-8. PubMed ID: 2856939
    [Abstract] [Full Text] [Related]

  • 3. Receptor binding of [3H]naloxone benzoylhydrazone: a reversible kappa and slowly dissociable mu opiate.
    Price M, Gistrak MA, Itzhak Y, Hahn EF, Pasternak GW.
    Mol Pharmacol; 1989 Jan; 35(1):67-74. PubMed ID: 2536470
    [Abstract] [Full Text] [Related]

  • 4. Affinity labeling of mu and kappa receptors with naloxone benzoylhydrazone.
    Standifer KM, Murthy LR, Kinouchi K, Steele L, Pasternak GW.
    Mol Pharmacol; 1991 Mar; 39(3):290-8. PubMed ID: 1848652
    [Abstract] [Full Text] [Related]

  • 5. Evidence for kappa 1 opioid receptor multiplicity in the guinea pig cerebellum.
    Kinouchi K, Pasternak GW.
    Eur J Pharmacol; 1991 Jun 19; 207(2):135-41. PubMed ID: 1679014
    [Abstract] [Full Text] [Related]

  • 6. Kappa agonists inhibit gastric emptying but not acid secretion in rhesus monkeys.
    Touzeau PL, Shea-Donohue T.
    J Pharmacol Exp Ther; 1990 Jun 19; 253(3):1010-6. PubMed ID: 1972746
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological activities of optically pure enantiomers of the kappa opioid agonist, U50,488, and its cis diastereomer: evidence for three kappa receptor subtypes.
    Rothman RB, France CP, Bykov V, De Costa BR, Jacobson AE, Woods JH, Rice KC.
    Eur J Pharmacol; 1989 Aug 29; 167(3):345-53. PubMed ID: 2553442
    [Abstract] [Full Text] [Related]

  • 8. Multiple opiate binding sites in the central nervous system of the rabbit. Large predominance of a mu subtype in the cerebellum and characterization of a kappa subtype in the thalamus.
    Meunier JC, Kouakou Y, Puget A, Moisand C.
    Mol Pharmacol; 1983 Jul 29; 24(1):23-9. PubMed ID: 6306437
    [Abstract] [Full Text] [Related]

  • 9. Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands.
    Zhu J, Luo LY, Li JG, Chen C, Liu-Chen LY.
    J Pharmacol Exp Ther; 1997 Aug 29; 282(2):676-84. PubMed ID: 9262330
    [Abstract] [Full Text] [Related]

  • 10. U50,488: a kappa-selective agent with poor affinity for mu1 opiate binding sites.
    Clark JA, Pasternak GW.
    Neuropharmacology; 1988 Mar 29; 27(3):331-2. PubMed ID: 2836756
    [Abstract] [Full Text] [Related]

  • 11. Discriminative stimulus effects of mu and kappa opioids in the pigeon: analysis of the effects of full and partial mu and kappa agonists.
    Picker MJ, Dykstra LA.
    J Pharmacol Exp Ther; 1989 May 29; 249(2):557-66. PubMed ID: 2566680
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological actions of a novel mixed opiate agonist/antagonist: naloxone benzoylhydrazone.
    Gistrak MA, Paul D, Hahn EF, Pasternak GW.
    J Pharmacol Exp Ther; 1989 Nov 29; 251(2):469-76. PubMed ID: 2553921
    [Abstract] [Full Text] [Related]

  • 13. Mu antagonist properties of kappa agonists in a model of rat urinary bladder motility in vivo.
    Sheldon RJ, Nunan L, Porreca F.
    J Pharmacol Exp Ther; 1987 Oct 29; 243(1):234-40. PubMed ID: 2822899
    [Abstract] [Full Text] [Related]

  • 14. Probes for narcotic receptor mediated phenomena. 17. Synthesis and evaluation of a series of trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacet amide (U50,488) related isothiocyanate derivatives as opioid receptor affinity ligands.
    de Costa BR, Rothman RB, Bykov V, Band L, Pert A, Jacobson AE, Rice KC.
    J Med Chem; 1990 Apr 29; 33(4):1171-6. PubMed ID: 2157008
    [Abstract] [Full Text] [Related]

  • 15. Reversible and irreversible binding of beta-funaltrexamine to mu, delta and kappa opioid receptors in guinea pig brain membranes.
    Tam SW, Liu-Chen LY.
    J Pharmacol Exp Ther; 1986 Nov 29; 239(2):351-7. PubMed ID: 3021954
    [Abstract] [Full Text] [Related]

  • 16. Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic.
    De Souza EB, Schmidt WK, Kuhar MJ.
    J Pharmacol Exp Ther; 1988 Jan 29; 244(1):391-402. PubMed ID: 2826773
    [Abstract] [Full Text] [Related]

  • 17. Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain.
    Rothman RB, Bykov V, de Costa BR, Jacobson AE, Rice KC, Brady LS.
    Peptides; 1990 Jan 29; 11(2):311-31. PubMed ID: 2162533
    [Abstract] [Full Text] [Related]

  • 18. Differential influence of D1 and D2 dopamine receptors on acute opiate withdrawal in guinea-pig isolated ileum.
    Capasso A, Sorrentino L.
    Br J Pharmacol; 1997 Mar 29; 120(6):1001-6. PubMed ID: 9134209
    [Abstract] [Full Text] [Related]

  • 19. Characteristics of opioid receptors in guinea-pig cerebellum and human placenta.
    Ishizuka Y, Oka T, Kenjo T, Fujii A.
    Tokai J Exp Clin Med; 1986 Aug 29; 11(3):179-84. PubMed ID: 3039693
    [Abstract] [Full Text] [Related]

  • 20. [3H]Ethylketocyclazocine binding to mouse brain membranes: evidence for a kappa opioid receptor type.
    Garzón J, Sánchez-Blázquez P, Lee NM.
    J Pharmacol Exp Ther; 1984 Oct 29; 231(1):33-7. PubMed ID: 6092603
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.